ERBB2 and breast cancer: Preclinical studies were initially conducted to analyze the immunogenicity of the E-75 peptide [54,55,56,57], followed by phase I trials such as NCT00841399, in which patients with metastatic BC and different HER2 expression were enrolled, and both doses and inoculation routes were optimized.